DelveInsight’s, “Spinal Cord Injury - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Spinal Cord Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Spinal Cord Injury Understanding
Spinal Cord Injury: Overview
Spinal Cord Injury (SCI) is a condition in which damage to any part of the spinal cord or nerves at the end of the spinal canal (cauda equina) occurs. Spinal Cord Injury can be traumatic or non-traumatic. The symptoms of SCI will depend on the type (complete or incomplete) and location of the damage and includes weakness in the arms and/or legs, difficulty breathing, severe pain or pressure in the neck or back, decreased sensation in the arms and/or legs, unusual lumps along the spine, and loss of bladder or bowel control. A diagnosis of SCI is based upon a medical history, physical examination, and testing for sensory function and movement. Tests may include X-rays, Computerized tomography (CT) scan, and Magnetic resonance imaging (MRI). Treatments for SCI includes surgery, medication and physical therapy. The primary aid or measures should be taken immediately to minimize the injury. Corticosteroid injections may help in spinal cord injuries.

"Spinal Cord Injury - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spinal Cord Injury pipeline landscape is provided which includes the disease overview and Spinal Cord Injury treatment guidelines. The assessment part of the report embraces, in depth Spinal Cord Injury commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinal Cord Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Spinal Cord Injury R&D. The therapies under development are focused on novel approaches to treat/improve Spinal Cord Injury.

Spinal Cord Injury Emerging Drugs Chapters
This segment of the Spinal Cord Injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spinal Cord Injury Emerging Drugs
• ES 135: Eusol Biotech
ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids. ES135 promote neurite outgrowth. The sequence of ES135 has been patented in Taiwan, EU, China and the United States. ES135 is undergoing a Phase 3 clinical trial for spinal cord injury treatment.

• MT-3921: Mitsubishi Tanabe Pharma Corporation
MT 3921 is a humanized immunoglobulin G1 (IgG1) anti- RGMa antibody. In July 2021, MT 3921 receives Fast Track designation for Spinal cord injuries [IV] (In the elderly, adults). The therapy is currently under Phase II clinical development for the treatment of Spinal Cord Injury.
Further product details are provided in the report……..

Spinal Cord Injury: Therapeutic Assessment
This segment of the report provides insights about the different Spinal Cord Injury drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Spinal Cord Injury
There are approx. 35+ key companies which are developing the therapies for Spinal Cord Injury. The companies which have their Spinal Cord Injury drug candidates in the most advanced stage, i.e. Phase III include, Eusol Biotech.

• Phases
DelveInsight’s report covers around 35+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Spinal Cord Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spinal Cord Injury: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Spinal Cord Injury therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal Cord Injury drugs.

Spinal Cord Injury Report Insights
• Spinal Cord Injury Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Spinal Cord Injury Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Spinal Cord Injury drugs?
• How many Spinal Cord Injury drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spinal Cord Injury?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spinal Cord Injury therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Spinal Cord Injury and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Kringle Pharma
• Eusol Biotech
• Pharmicell
• Pharmazz
• AbbVie
• Acorda Therapeutics
• Geron Corporation
• ReNetX Bio
• GNT Pharma
• AlaMab Therapeutics
• Mitsubishi Tanabe Pharma
• Kancera
• Olatec Therapeutics
• Scholar Rock
• AXONIS Therapeutics
• K-STEMCELL
• Nordic Life Science Pipeline
• NervGen Pharma
• Athersys
• Healios
• Angiocrine Bioscience

Key Products
• Hepatocyte growth factor
• ES 135
• Autologous mesenchymal stem cell therapy
• Sovateltide
• Elezanumab
• Fampridine sustained release
• OPC 1
• AXER-204
• Nelonemdaz
• ALMB 0166
• MT-3921
• KAND 567
• Dapansutrile
• Apitegromab
• AAV gene therapy
• Stem cell therapies
• Spinalon
• NVG 291
• Invimestrocel
• AB-225